ADIPOQ and diabetic kidney disease: Activated PPARγ delayed the progress of DKD by improving insulin resistance [27], lowering blood pressure [28], ameliorating inflammation [29], reversing cell cycle arrest [30], increasing adiponectin [31], improving oxidative stress [32], and other mechanisms.